Head‐to‐head comparison of three chelates reveals DOTAGA promising for 225 Ac labeling of anti‐FZD10 antibody OTSA101
Cancer Science · 2023-12 · 114 (12) · 4677-4690
DOI: 10.1111/cas.15978 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 02.10.2023. Verfasst von Hitomi Sudo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology (QST), Chiba, Japan. Hauptthemen laut MEDLINE: Chelating Agents, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
To select the most suitable chelate for 225 Ac radiolabeling of the anti‐FZD10 antibody OTSA101, we directly compared three chelates: S ‐2‐(4‐isothiocyanatobenzyl)‐1,4,7,10‐tetraazacyclododecane tetraacetic acid ( p ‐SCN‐Bn‐DOTA), 2,2′,2″‐(10‐(1‐carboxy‐4‐((4‐isothiocyanatobenzyl)amino)‐4‐oxobutyl)‐1,4,7,10‐tetraazacyclododecane‐1,4,7‐triyl) triacetic acid ( p ‐SCN‐Bn‐DOTAGA), and 1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐tetraacetic acid mono‐ N ‐hydroxysuccinimide ester (DO3A‐NHS‐ester). We evaluated the binding affinity of the chelate‐conjugated OTSA101 antibodies, as well as the labeling efficiency and stability in murine serum of 225 Ac‐labeled OTSA101 as in vitro properties. The biodistribution, intratumoral distribution, absorbed doses, and therapeutic effects of the chelate‐conjugated OTSA101 antibodies were assessed in the synovial sarcoma mouse model SYO‐1. Of the three conjugates, DOTAGA conjugation had the smallest impact on the binding affinity ( p < 0.01). The labeling efficiencies of DOTAGA‐OTSA101 and DO3A‐OTSA101 were 1.8‐fold higher than that of DOTA‐OTSA101 ( p < 0.01). The stabilities were similar between 225 Ac‐labeled DOTA‐OTSA101, DOTAGA‐OTSA101, and DO3A‐OTSA101in serum at 37 and 4°C. The dosimetric analysis based on the biodistribution revealed significantly higher tumor‐absorbed doses by 225 Ac‐labeled DOTA‐OTSA101 and DOTAGA‐OTSA101 compared with 225 Ac‐DO3A‐OTSA101 ( p < 0.05). 225 Ac‐DOTAGA‐OTSA101 exhibited the highest tumor‐to‐bone marrow ratio, with bone marrow being the dose‐limiting tissue. The therapeutic and adverse effects were not significantly different between the three conjugates. Our findings indicate that among the three evaluated chelates, DOTAGA appears to be the most promising chelate to produce 225 Ac‐labeled OTSA101 with high binding affinity and high radiochemical yields while providing high absorbed doses to tumors and limited absorbed doses to bone marrow.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
- OncoTherapy Science, Kawasaki, Japan.
- Department of Surgery, Uji Tokushukai Medical Center, Uji, Japan.
- Division of Genome Medicine, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
- National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan.
ORCID-Profile: Atsushi B Tsuji, Satoshi Nagayama, Toyomasa Katagiri
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Sudo, H., Tsuji, A. B., Sugyo, A., Harada, Y., Nagayama, S., Katagiri, T., Nakamura, Y., & Higashi, T. (2023). Head‐to‐head comparison of three chelates reveals DOTAGA promising for 225 Ac labeling of anti‐FZD10 antibody OTSA101. Cancer Science, 114(12), 4677-4690. https://doi.org/10.1111/cas.15978
Vancouver
Sudo H, Tsuji AB, Sugyo A, Harada Y, Nagayama S, Katagiri T, et al. Head‐to‐head comparison of three chelates reveals DOTAGA promising for 225 Ac labeling of anti‐FZD10 antibody OTSA101. Cancer Science. 2023;114(12):4677-4690. doi:10.1111/cas.15978
BibTeX
@article{Sudo2023,
author = {Sudo, Hitomi and Tsuji, Atsushi B and Sugyo, Aya and Harada, Yosuke and Nagayama, Satoshi and Katagiri, Toyomasa and Nakamura, Yusuke and Higashi, Tatsuya},
title = {Head‐to‐head comparison of three chelates reveals DOTAGA promising for 225 Ac labeling of anti‐FZD10 antibody OTSA101},
journal = {Cancer Science},
year = {2023},
volume = {114},
number = {12},
pages = {4677--4690},
doi = {10.1111/cas.15978}
}
EUVIMED